Oppenheimer Initiates Outperform Coverage on Palisade Bio with $8 Price Target
Strong bullish case for its oral IBD therapy ahead of Phase 2 data.
Strong bullish case for its oral IBD therapy ahead of Phase 2 data.
Morgan Stanley initiates coverage on RIOT, HUT & APLD with strong price targets. See massive upside potential of up to +139% as Bitcoin miners turn into AI power providers.
RTX raises 2026 sales and profit forecasts after strong Q2 results driven by aircraft maintenance and defense demand.
STMicroelectronics reported $3.49B revenue (+26% YoY) in Q2 2026 and raised its AI outlook, but missed EBITDA estimates and issued softer guidance, sending shares down 14%.
The move strengthens Progress’s AI infrastructure and data governance capabilities.
Nokia’s results look solid, but growth is modest. Strong AI orders and mobile gains offset weaker optical performance; investors remain cautious.